TAPA-pulsed DC vaccine

BIOLOGICAL4 trials

Sponsors

Kiromic BioPharma Inc.

Conditions

CancerHematologic MalignanciesMetastatic Solid MalignanciesProgressive Solid MalignanciesRefractory Solid Malignancies

Phase 1

Therapy for Progressive and/or Refractory Hematologic Malignancies

WithdrawnNCT02223312

Kiromic BioPharma Inc.Cancer, Hematologic Malignancies

Start: 2017-07-28End: 2019-01-31Updated: 2018-08-28

Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies

TerminatedNCT02224599

Kiromic BioPharma Inc.Cancer, Progressive Solid Malignancies, Refractory Solid Malignancies

Start: 2017-07-28End: 2018-08-30Updated: 2020-04-24

Consolidation Therapy in Patients With Metastatic Solid Malignancies

WithdrawnNCT02705703

Kiromic BioPharma Inc.Cancer, Metastatic Solid Malignancies

Start: 2017-07-28End: 2019-01-31Updated: 2018-08-28

Consolidation Therapy in Patients With Hematologic Malignancies

WithdrawnNCT02709993

Kiromic BioPharma Inc.Cancer, Hematologic Malignancies

Start: 2017-07-28End: 2020-10-31Updated: 2019-10-14

Related Papers

Preliminary report of a novel formulation of clinical-grade, fully matured, tumor-associated peptide-loaded dendritic cells for cancer immunotherapy

Translational Medicine Communications2019-11-175 citations

Combination therapy of dendritic cell vaccination plus chemotherapy in pancreatic cancer.

Journal of Clinical Oncology2019-05-203 citations

Phase I/II study of BSK01, an artificial intelligence-driven, peptide-pulsed, mature DC immunotherapy for solid and hematological malignancies.

Journal of Clinical Oncology2018-05-201 citations

Phase I/II study of low-dose cyclophosphamide, tumor-associated peptide antigen-pulsed dendritic cell and low dose GM-CSF for solid and hematological tumors.

Journal of Clinical Oncology2018-02-101 citations